[1] 谷铣之, 殷蔚伯, 余子豪, 等. 肿瘤放射治疗学(第四版)[M]. 北京: 中国协和医科大学出版社, 2008: 546-577.
[2] Yamashita H, Okuma K, Seto Y. A retrospective comparison of clinical outcomes and quality of life measures between definitive chemoradiation alone and radical surgery for clinical stageⅡⅢ esophagealcarcinoma[J]. J Surg Oncol, 2009, 100(6): 435-441. DOI: 10.1002/jso.21361.
[3] 李国文, 郭跃信. 80岁以上老年人食管癌的放射治疗[J]. 中华老年医学杂志, 2007, 26(3): 202-203. DOI: 10.3760/j.issn.0254-9026.2007.03.014.
[4] Caravatta L, Picardi V, Tambaro R, et al. Neoadjuvant accelerated concomitant boost radiotherapy and multidrug chemotherapy in locally advanced rectal cancer: a dose escalation study[J]. Am J Clin Oncol, 2012, 35(5): 424-431. DOI: 10.1097/COC.0b013e31821a5844.
[5] 王佳蕾, 李进, 秦叔逵, 等. 雷替曲塞或氟尿嘧啶/亚叶酸钙联合奥沙利铂治疗局部晚期或复发转移结直肠癌的随机对照多中心Ⅲ期临床试验[J]. 临床肿瘤学杂志, 2012, 17(1): 6-11.
[6] Shen J, Wang H, Wei J, et al. Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer[J]. Int J Cancer, 2012, 131(6): E938-945. DOI: 10.1002/ijc.27530.
[7] Surmont VF, van Meerbeeck JP. Raltitrexed in mesothelioma[J]. Expert Rev Anticancer Ther, 2011, 11(10): 1481-1490. DOI: 10.1586/era.11.136.
[8] 夏铀铀, 王磊, 宋大安, 等. 放疗联合雷替曲塞 奥沙利铂同步治疗中晚期食管癌的Ⅱ期临床研究[J]. 中国肿瘤临床, 2014, 41(11): 716-719. DOI: 10.3969/j.issn.1000-8179.20140440.
[9] 李德凡, 杨帆, 蒋淑年, 等. 三维适形放疗联合雷替曲塞加奥沙利铂治疗中晚期食管鳞癌的临床观察[J]. 临床肿瘤学杂志, 2015, 20(1): 57-60.
[10] 吕会来, 温士旺, 李勇, 等. 雷替曲塞单药治疗老年晚期食管癌疗效观察[J]. 河北医药, 2015, 37(9): 1382-1383. DOI: 10.3969/j.issn.10027386.2015.09.036.
[11] Ransom D, Wilson K, Fournier M, et al. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines[J]. Ann Oncol, 2014, 25(1): 117-121. DOI: 10.1093/annonc/mdt479. |